Dr Jim Phillips has joined Innomedica in the beginning of March, to run Innomedica’s UK office. He will be serving Innomedica’s clients especially in the areas of global licensing and market access.
“Jim’s senior executive experience from big pharma and a track record of more than 15 highly successful license agreements, mergers and acquisitions will benefit our clients tremendously”, says Innomedica’s Managing Director Tanja Dowe. “Jim also knows the reality of early stage ventures, having led a number of drug discovery and medical technology companies from establishment to a successful exit.”
Innomedica aims at European leadership in market access services. “Innomedica has a great business concept and a brand. Innomedica’s Japan market access on such a top management level is unbeatable,” explains Dr Phillips. “I am very excited to help Innomedica expand their business in UK and France”.
Dr Phillips has over 20 years healthcare industry experience, and is a qualified physician with an MBA from Cass Business School. He worked for Johnson & Johnson , and Novartis in senior executive roles, and was founder & chief executive officer of Talisker Pharmaceuticals Ltd, which was acquired by EUSA Pharma Inc in July 2006 giving investors a successful exit. Jim also took Bone Medical Ltd through its oversubscribed IPO in Australia in 2004 as Chief Executive.
Dr Phillips has held a number of other international board level roles including organizations such as West Sussex Health Authority, Lifegard Technologies Ltd, CRF Inc, Diabetology Ltd, EUSA Pharma Inc, OPi S.A., Vantia Ltd. He has extensive experience in business development in pharmaceuticals, and in developing early stage ventures.
Innomedica is a business consulting company specialized in market access services for life sciences companies. Innomedica was founded in 1997, and is a privately held company. Innomedica operates on a global basis with offices in Helsinki, Turku, Tokyo and London.
Tanja Dowe, Managing Director, tel. +358-400 636 107